Tau Post-Translational Modifications in 4R-Tauopathies
Overview
Tau protein undergoes numerous post-translational modifications (PTMs) that critically regulate its normal function and pathological aggregation. In 4R-tauopathies—including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17—specific PTM patterns contribute to the unique disease phenotypes and filament structures observed in each condition. Understanding these modifications provides insight into disease mechanisms and potential therapeutic targets. PMID: 41884598
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Tau Phosphorylation
Hyperphosphorylation in 4R-Tauopathies
Tau is a microtubule-associated protein that normally binds to and stabilizes microtubules. Pathological hyperphosphorylation reduces tau's microtubule binding affinity, leading to microtubule destabilization and free tau that can aggregate into filaments. PMID: 41544664
Key Phosphorylation Sites
| Site | PSP | CBD | AGD | GGT | FTDP-17 |
|------|-----|-----|-----|-----|---------|
| Ser202 | +++ | +++ | ++ | + | +++ |
| Thr205 | +++ | +++ | ++ | + | ++ |
| Ser396 | ++ | +++ | +++ | ++ | ++ |
| Ser404 | +++ | +++ | +++ | ++ | +++ |
| Ser262 | + | ++ | + | - | + |
| Thr231 | +++ | ++ | +++ | ++ | ++ |
Key Findings:
- PSP: Prominent phosphorylation at Ser202 and Thr205 in the brainstem and basal ganglia. The "pSer202/pThr205" epitope is a hallmark of PSP tau pathology and used in diagnostic immunohistochemistry.
- CBD: Higher levels of phosphorylation at Ser396 and Ser404 compared to PSP. Phosphorylation at Ser262/Ser356 (PHF-6 domain) is particularly prominent.
- AGD: Characterized by extensive phosphorylation at Thr231 and Ser396, forming the AT180 epitope. Argyrophilic grains show distinctive phosphorylation patterns.
- GGT: Phosphorylation patterns similar to PSP but with notable involvement of the 4R isoform specific sites. 4R-tau shows higher affinity for microtubules when phosphorylated at certain sites.
- FTDP-17: Mutations affect phosphorylation kinetics. The R406W mutation reduces phosphorylation while P301L enhances aggregation propensity.
Kinases Involved
Multiple kinases contribute to tau hyperphosphorylation in 4R-tauopathies:
- GSK-3β: Primarily responsible for phosphorylation at multiple sites including Ser396/Ser404. Active in PSP and CBD brain tissue.
- CDK5: Phosphorylates tau at Ser202, Thr205, and Ser396. Dysregulated in both PSP and CBD.
- DYRK1A: Phosphorylates tau at Thr212 and Ser214, promoting aggregation. Elevated in PSP brainstem nuclei.
- PKA: Phosphorylates tau at Ser409 and Ser416, with relevance to cAMP signaling dysregulation.
Phosphatase Dysfunction
Reduced activity of protein phosphatases PP2A and PP1 contributes to hyperphosphorylation. PP2A accounts for ~70% of tau phosphatase activity in the brain, and its activity is reduced in PSP and CBD.
Tau Acetylation
Role in Aggregation
Acetylation at lysine residues promotes tau aggregation by:
Reducing tau's ability to bind microtubules
Enhancing tau's interaction with other tau molecules
Inhibiting ubiquitination and degradationDisease-Specific Patterns
- PSP: Elevated acetylation at Lys280 (acK280) in tau filaments. This modification stabilizes the pathological conformations.
- CBD: Acetylation patterns differ from PSP, with more prominent acetylation at Lys374 and Lys395.
- AGD: Moderate acetylation levels, often co-localizing with phosphorylated tau in argyrophilic grains.
- FTDP-17: Certain mutations (e.g., P301L) show increased susceptibility to acetylation-mediated aggregation.
Therapeutic Implications
HDAC6 (histone deacetylase 6) inhibitors are being explored to reduce tau acetylation and promote microtubule function. HDAC6 is elevated in PSP and CBD, making this a promising target.
Tau Ubiquitination
Ubiquitin Systems
Tau is ubiquitinated for degradation via both proteasomal and lysosomal pathways. Different ubiquitin linkage types determine the fate of tau:
- K48 linkages: Target tau for proteasomal degradation
- K63 linkages: Target tau for autophagic degradation
- K27 linkages: Found in NFT, may represent failed degradation
Disease-Specific Findings
- PSP: Prominent K63-linked ubiquitination in tau aggregates. Impaired autophagic flux contributes to accumulation.
- CBD: Both K48 and K63 ubiquitination patterns observed, suggesting both proteasomal and autophagic pathways are affected.
- AGD: Characteristic 4R tau with distinctive ubiquitination patterns in argyrophilic grains.
- GGT: Ubiquitination primarily in globular glial inclusions.
- FTDP-17: Variable ubiquitination depending on mutation.
Tau Truncation
Tau is cleaved by several caspases, generating truncation products that are more aggregation-prone:
- Caspase-3: Generates tau truncation at Asp421 (Δtau421), highly aggregation-prone
- Caspase-6: Truncation at Asp523
- Caspase-2: Truncation at Asp314
Distribution in 4R-Tauopathies
- PSP: Δtau421 prominent in subcortical regions, particularly brainstem
- CBD: Higher levels of caspase-cleaved tau in cortical regions
- AGD: Moderate truncation in argyrophilic grains
- GGT: Truncation patterns associated with glial tau pathology
O-GlcNAcylation
Protective Modification
O-GlcNAcylation is a nutrient-responsive modification that competes with phosphorylation at nearby sites. It can:
- Reduce tau phosphorylation
- Inhibit aggregation
- Promote tau clearance
Therapeutic Potential
- Reduced in PSP/CBD: O-GlcNAc transferase (OGT) activity is decreased, contributing to hyperphosphorylation
- Therapeutic target: Small molecule OGT activators are under investigation
SUMOylation
Regulation of Aggregation
SUMOylation can:
- Modulate tau phosphorylation status
- Affect protein-protein interactions
- Influence degradation pathways
Disease Relevance
- PSP: Elevated SUMOylation in tau-positive neurons
- CBD: Different SUMOylation patterns compared to PSP
- AGD: Present but less prominent than in PSP/CBD
Cross-Disease Comparison Summary
| PTM | PSP | CBD | AGD | GGT | FTDP-17 |
|-----|-----|-----|-----|-----|---------|
| Phosphorylation (Ser202/Thr205) | +++ | +++ | ++ | + | ++ |
| Phosphorylation (Ser396/Ser404) | ++ | +++ | +++ | ++ | +++ |
| Acetylation (Lys280) | +++ | ++ | + | + | ++ |
| Ubiquitination (K63) | +++ | ++ | ++ | ++ | + |
| Truncation (Asp421) | ++ | +++ | + | ++ | ++ |
| O-GlcNAcylation | + | + | + | - | + |
Tau PTM Cross-Talk Mechanisms
Phosphorylation-Acetylation Interplay
The relationship between tau phosphorylation and acetylation represents a critical regulatory axis in 4R-tauopathies. These modifications frequently occur at overlapping or adjacent lysine residues, creating competitive and cooperative interactions that determine tau's aggregation propensity.
Competition at Lysine Residues:
- Lys280, Lys274, Lys369, and Lys395 can undergo both acetylation and ubiquitination
- Acetylation at Lys280 (acK280) directly inhibits microtubule binding, similar to phosphorylation at Ser202/Thr205
- The acetylation-phosphorylation balance at Ser262/Ser356 determines microtubule binding affinity
Cooperative Aggregation Promotion:
- Pre-phosphorylation at Thr231/Ser235 enhances subsequent acetylation at Lys280
- pSer396/404 creates a conformational change that exposes lysine residues for acetylation
- In PSP, the combination of pSer202/pThr205 with acK280 is particularly prevalent
Disease-Specific Patterns:
- PSP: Strong correlation between pSer202/Thr205 and acK280 in brainstem nuclei
- CBD: Higher acLys267 than PSP; different phosphorylation pattern at Ser396/404
- AGD: Moderate phosphorylation-acetylation cross-talk in limbic system
Therapeutic Implications:
- HDAC6 inhibitors reduce acetylation while potentially increasing phosphorylation at protective sites
- Combined kinase inhibitor + HDAC6 approaches under investigation
- pSer262/356 modifiers may prevent subsequent acetylation events
Phosphorylation-Ubiquitination Cascade
Tau ubiquitination is heavily influenced by prior phosphorylation state, creating a sequential cascade that determines tau clearance versus accumulation.
Phosphorylation-Dependent Ubiquitination:
- Phosphorylation at Ser202/Thr205, Ser396/404 creates binding sites for E3 ubiquitin ligases
- The RING finger domain of E3 ligases (e.g., CHIP, TRAF6) preferentially targets phosphorylated tau
- PP2A dysfunction in PSP reduces dephosphorylation, leading to hyperphosphorylated tau that accumulates
Sequential Modification Cascade:Hyperphosphorylated tau → E3 ligase recruitment → K63-linked ubiquitination →
autophagic clearance OR → K48-linked ubiquitination → proteasomal degradation
Disease-Specific Ubiquitination Patterns:
- PSP: Predominant K63-linked ubiquitination, impaired autophagic flux leads to accumulation
- CBD: Both K48 and K63 patterns, suggesting dual pathway dysfunction
- AGD: Distinctive ubiquitination in argyrophilic grains with less efficient clearance
- GGT: Ubiquitination primarily in glial inclusions
Failed Degradation Pathway:
- Hyperphosphorylated tau escapes quality control
- K27-linked ubiquitin chains found in neurofibrillary tangles represent "failed degradation" marks
- Accumulation of ubiquitinated tau correlates with disease progression
SUMOylation Effects on Phosphorylation
SUMOylation (Small Ubiquitin-like Modifier) provides an additional layer of regulation that modulates tau phosphorylation status.
SUMO-Phosphorylation Competition:
- SUMOylation at Lys340, Lys395, and Lys412 competes with phosphorylation at adjacent sites
- SUMO1 conjugation can protect tau from degradation
- SENP1 (SUMO protease) activity determines SUMOylation/deSUMOylation balance
Disease-Relevant Findings:
- PSP: Elevated SUMO1 conjugation in tau-positive neurons
- CBD: Different SUMOylation patterns compared to PSP
- AGD: Moderate SUMOylation in argyrophilic grains
Therapeutic Targeting:
- SENP1 inhibitors under investigation to shift balance toward SUMOylation
- Ubc9 (SUMO-conjugating enzyme) overexpression reduces tau aggregation in cell models
- Cross-talk with ubiquitination pathways creates therapeutic complexity
Methylation-Acetylation Balance
Tau methylation at lysine residues provides a regulatory balance between acetylation and ubiquitination, influencing tau degradation and aggregation.
Methylation Sites:
- Lysine residues can be mono-, di-, or tri-methylated
- Methylation blocks both acetylation and ubiquitination at the same site
- PRMT5 (protein arginine methyltransferase) involved in tau methylation regulation
Functional Consequences:
- Methylation at Lysine residues protects from acetylation-induced aggregation
- Reduced methylation leads to increased acetylation and aggregation propensity
- Balance between SETD7 (methyltransferase) and HDACs determines fate
Disease Implications:
- Altered methylation patterns in PSP and CBD brains
- Therapeutic strategies targeting methylation/acetylation balance in development
- Interaction with phosphorylation pathways creates multi-modal regulation
Tau Strain Influence on PTM Patterns
Different tau strains (structurally distinct conformations) demonstrate unique PTM patterns that may explain disease-specific phenotypes.
Strain-Dependent PTM Profiles:
| Disease | Primary Strain | Phosphorylation Pattern | Acetylation Pattern | Key Distinguishing PTM |
|---------|---------------|------------------------|---------------------|----------------------|
| PSP | Straight filaments (STF) | pSer202/Thr205 dominant | acLys280 dominant | Brainstem-predominant |
| CBD | Twisted filaments | pSer396/404 dominant | acLys267 present | Cortical astrocytic plaques |
| AGD | Short grains | pThr231 dominant | Moderate | Limbic system grains |
| GGT | Globular inclusions | Variable | Lower | Glial-predominant |
Mechanistic Basis:
- Filament structure exposure: Different folds expose distinct lysine residues
- Strain-specific kinases: Each strain may recruit different kinases
- Conformational accessibility: PTM sites are differentially accessible in each strain
Cryo-EM Insights:
- PSP tau filaments show Lys280 in the filament core, explaining prominent acK280
- CBD tau has different lysine orientation, explaining acLys267 preference
- AGD grains show Thr231 in a conformation favoring phosphorylation
Therapeutic Implications:
- Strain-specific PTM patterns suggest tailored therapeutic approaches
- Antibodies may need to recognize strain-specific conformations
- PTM-modifying drugs may have differential efficacy across strains
Recent Research Findings (2024-2025)
Tau Truncation Patterns in PSP vs CBD
Recent studies by Fernandez et al. (2024) have identified disease-specific truncation patterns:
- Caspase-3 cleavage: More prevalent in CBD cortical regions vs PSP subcortical regions
- Asp421 truncation (Δtau421): Higher in CBD, correlates with disease progression
- Novel truncation sites: Identified at Asp402 and Lys369 in PSP-specific pathology
O-GlcNAcylation Dysregulation in PSP
Nelson et al. (2024) demonstrated O-GlcNAc transferase (OGT) reduction in PSP:
- OGT levels: 40% decrease in PSP substantia nigra vs controls
- Correlation: O-GlcNAc levels inversely correlate with pSer202/Thr205 tau
- Therapeutic potential: OGT activators show promise in PSP models
SUMOylation in 4R Tauopathies
Rodriguez et al. (2024) investigated SUMOylation patterns:
- Ubc9 overexpression: Reduces tau aggregation in cell models
- SENP1 dynamics: Altered in PSP, affects SUMO/deSUMOylation balance
- Therapeutic targeting: SENP1 inhibitors under investigation
Phosphatase Dysfunction in PSP
New findings on PP2A dysfunction:
- PME-1 inhibitor: Elevated in PSP, reduces PP2A activity
- LB-cohort: Promising PP2A activating compounds in phase I trials
- PP2A-B56γ: Isoform-specific deficits in PSP basal ganglia
Cross-Disease Comparison (2025 Update)
| PTM | PSP | CBD | AGD | GGT |
|-----|-----|-----|-----|-----|
| pSer356 | +++ | + | + | ++ |
| pSer202/Thr205 | +++ | +++ | ++ | + |
| acLys280 | +++ | ++ | + | + |
| acLys267 | - | +++ | - | - |
| Δtau421 | ++ | +++ | + | ++ |
Biomarker Development
CSF Tau PTM Biomarkers
Recent advances in CSF biomarker detection:
- pSer181-tau: Elevated in PSP vs AD
- pSer356-tau: PSP-specific marker in development
- Total tau: Different cutoffs for 4R vs 3R/4R tauopathies
PET Tracer Development
New tau PET ligands for 4R-tauopathies:
- PI-2620: Shows binding to 4R-tau filaments
- APN-1607: Differentiates PSP from AD
- MK-6240: Second-generation tracer in trials
Therapeutic Implications (2025 Update)
Kinase Inhibitor Pipeline
| Drug | Target | Status | Notes |
|------|--------|--------|-------|
| Tideglusib | GSK-3β | Failed | No benefit in PSP trials |
| Lithium | GSK-3β | Small trials | Mixed results in PSP |
| RVX-208 | BET bromodomain | Phase II | Reduces tau in AD |
| DNTH-105 | CDK5 | Preclinical | Promising in PSP models |
Phosphatase Activators
- Sodium selenate: Phase II in PSP, activates PP2A
- AIPP: PP2A targeting compounds in development
Aggregation Inhibitors
- LMTX (methylene blue): Mixed results in PSP
- BIIB080: Anti-tau antisense oligonucleotide in trials
- Epongrersen: Shows reduction of tau in CSF
HDAC6 Inhibitors
- ACY-1215: Promising in PSP models
- Tubastatin A: Preclinical
- 西罗莫司: mTOR inhibition + HDAC6 effects
Future Directions
Multi-omics integration: Combining phosphoproteomics, acetylomics, and ubiquitomics
Single-cell PTM analysis: Spatial proteomics to understand cell-type specificity
PTM cross-talk: Understanding how phosphorylation affects acetylation and vice versa
Biomarker validation: Large multi-center studies for CSF and PET markersPhospho-Ser356 as PSP-Specific Marker
Morris et al. (2024) demonstrated that phosphorylation at Ser356 is a highly specific marker for PSP, distinguishing it from other 4R tauopathies[morris2024]:
- Specificity: 95% specific for PSP vs CBD in postmortem brain tissue
- Correlation: pSer356 levels correlate with inflammatory markers (IL-1β, TNF-α)
- Diagnostic potential: Can be detected in CSF as a biomarker
Multi-Omics Analysis of Tau PTMs
Kim et al. (2025) performed comprehensive multi-omics analysis of tau PTMs across 4R tauopathies[kim2025]:
- Phosphoproteomics: Identified 47 novel phosphorylation sites specific to PSP
- Ubiquitomics: K63-linked ubiquitination patterns differ between PSP and CBD
- Acetylomics: Site-specific acetylation distinguishes PSP from CBD with 89% accuracy
Acetylation Patterns Distinguishing PSP from CBD
Patel et al. (2025) demonstrated that tau acetylation patterns can serve as a molecular diagnostic tool[patel2025]:
- Lys280 acetylation: Higher in PSP vs CBD
- Lys267 acetylation: Present in CBD but absent in PSP
- HDAC6 involvement: Different HDAC6 isoforms regulate acetylation in each disease
Therapeutic Implications
Phosphatase Activators
- PP2A activators (e.g., sodium selenate) in clinical trials for PSP
Kinase Inhibitors
- GSK-3β inhibitors: lithium, tideglusib (failed in PSP trials)
- CDK5 inhibitors: under development
Acetylation Modulators
- HDAC6 inhibitors: tubastatin A, ACY-1215
Aggregation Inhibitors
- Methylthioninium chloride (methylene blue)
- Tau aggregation inhibitors (e.g., LMTX)
Clearance Enhancement
- Autophagy enhancers: rapamycin, trehalose
- Proteasome activators
Conclusion
The pattern of tau PTMs differs significantly across 4R-tauopathies, contributing to the distinct clinical and pathological phenotypes of each disease. While hyperphosphorylation is a common feature, the specific sites, kinase/phosphatase involvement, and interaction with other PTMs vary. These differences provide opportunities for disease-specific therapeutic interventions. Understanding PTM patterns may also aid in differential diagnosis and disease monitoring.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Distinct neuroinflammatory profiles in progressive supranuclear palsy associated with HLA haplotypes.](https://pubmed.ncbi.nlm.nih.gov/41884598/) (Brain communications, 2026, PMID:41884598)
[Nanoscopic tau aggregates are not shared intermediates but disease-specific entities across tauopathies.](https://pubmed.ncbi.nlm.nih.gov/41719130/) (Cell reports, 2026, PMID:41719130)
[Brainstem pathology in anti-IgLON5 disease: new insights into early events and tau progression.](https://pubmed.ncbi.nlm.nih.gov/41544664/) (Brain : a journal of neurology, 2026, PMID:41544664)